Print Page      Close Window

Investor Overview

Corporate Profile

Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within. Tocagen is currently studying its lead product candidate, Toca 511 & Toca FC, in a Phase 3 clinical trial for the treatment of patients with recurrent high grade glioma (HGG), a type of brain cancer with limited treatment options. Toca 511 & Toca FC has been granted Breakthrough Therapy Designation for the treatment of patients with recurrent HGG by the FDA, and PRIME (PRIority MEdicines) designation by the European Medicines Agency.
NASDAQ GS TOCA (Common Stock)
$12.40 - 0.34
Stock chart for: TOCA.O.  Currently trading at $12.40 with a 52 week high of $17.95 and a 52 week low of $8.60.
03/22/18 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News

View All  

Tocagen to Present Preliminary Toca 6 Phase 1 Data and Immune Profiling Data at the American Association for Cancer Research (AACR) Annual Meeting 2018


Read More

Tocagen to Present at the B. Riley FBR China Healthcare Investment & Partnering Symposium 2018


Read More

Tocagen Reports Fourth Quarter and Full Year 2017 Financial and Business Results


Read More

Recent Presentation

View All  
Download Documentation  Corporate Presentation – February 2018
Download Documentation Durable Responses Observed in Recurrent High Grade Glioma (rHGG) with Toca 511 & Toca FC Treatment

Upcoming Events

View All  
There are currently no events scheduled.